In contrast, the upregulation of FANCD2 was positively associated with tumor size and a poor prognosis in breast cancer, ovarian cancer, nasopharyngeal carcinoma, glioblastoma, endometrial carcinoma, and esophageal squamous cell carcinoma [59–65]. Here, FANCD2 is linked to ovarian cancer.